The Limited Times

Now you can see non-English news...

Acne, chlamydia ... Sanofi is launching new vaccines


The laboratory, number four in the world in the sector, hopes to have ten new candidate vaccines in clinical development by 2025, six of which are based on messenger RNA.

“Much has been said about Sanofi and its vaccine business, given that we were not one of two labs with an approved messenger RNA Covid vaccine.

Let's be clear: I don't see much potential impact at this stage (…).

We are perfectly positioned to play an important role in the vaccine market. ”

While Sanofi's anti-Covid vaccine is still long overdue, Paul Hudson, its CEO, has tried to change gear.

The first French laboratory, which announced almost a year ago to the day several months of delay in its clinical trials, still hopes to publish the results of the final phase of tests

"in the next few weeks".

To read also

Stéphane Bancel: "In 12 to 18 months, Moderna will have the scale of a Roche or Novartis"

If they are positive, Sanofi continues to bet on a “booster” strategy but its vaccine would only have a complementary role, at least during the pandemic phase.

"The stake for us is not financial,

insists Thomas Triomphe, at the head of the vaccines activity of Sanofi (16.5% of the turnover).

This article is for subscribers only.

You have 69% left to discover.

To cultivate one's freedom is to cultivate one's curiosity.

Continue reading your article for € 1 the first month


Already subscribed?

Log in

Source: lefigaro

All business articles on 2021-12-01

You may like

Business 2021-09-06T19:16:28.849Z

Trends 24h


© Communities 2019 - Privacy